Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 1/2020

25.10.2019 | Letter to the Editor

Life after abciximab; what’s next for intracoronary thrombus?

verfasst von: D. McGhie, D. Amos, A. Elder, D. Brieger, H. C. Lowe

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

A case is described in which the short-acting glycoprotein IIb/IIIa receptor antagonist tirofiban was used in combination with heparin, aspirin and prasugrel to successfully treat extensive intracoronary thrombus in a delayed presentation STEMI, illustrating the utility of this approach.
Literatur
1.
Zurück zum Zitat Chew DP, Scott IA, Cullen L et al (2016) National heart foundation of Australia & cardiac society of Australia and new zealand: Australian Clinical Guidelines for the management of acute coronary syndromes 2016. Heart Lung Circ 25:895–951CrossRef Chew DP, Scott IA, Cullen L et al (2016) National heart foundation of Australia & cardiac society of Australia and new zealand: Australian Clinical Guidelines for the management of acute coronary syndromes 2016. Heart Lung Circ 25:895–951CrossRef
2.
Zurück zum Zitat Hernandez J, Sagredo M, Arrieta M et al (2017) Antithrombotic treatment during coronary angioplasty after failed thrombolysis: strategies and prognostic implications: Results of the RESPIRE registry. BMC Cardiovasc Disord 17:212CrossRef Hernandez J, Sagredo M, Arrieta M et al (2017) Antithrombotic treatment during coronary angioplasty after failed thrombolysis: strategies and prognostic implications: Results of the RESPIRE registry. BMC Cardiovasc Disord 17:212CrossRef
3.
Zurück zum Zitat Petronio AS, Musumeci G, Limbruni IJ et al (2002) Abciximab improves 6-month clinical outcome after rescue coronary angioplasty. Am Heart J 143:334–341CrossRef Petronio AS, Musumeci G, Limbruni IJ et al (2002) Abciximab improves 6-month clinical outcome after rescue coronary angioplasty. Am Heart J 143:334–341CrossRef
5.
Zurück zum Zitat Neuman FJ, Hockholzer W, Pogatsa-Murray G, Schomig A, Gawaz M (2001) Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. J Am Coll Cardiol 37:1323–1328CrossRef Neuman FJ, Hockholzer W, Pogatsa-Murray G, Schomig A, Gawaz M (2001) Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. J Am Coll Cardiol 37:1323–1328CrossRef
6.
Zurück zum Zitat The RESTORE investigators (1997) Effects of platelet glycoprotein IIB/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or myocardial infarction undergoing coronary angioplasty. Circulation 96:1445–1453CrossRef The RESTORE investigators (1997) Effects of platelet glycoprotein IIB/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or myocardial infarction undergoing coronary angioplasty. Circulation 96:1445–1453CrossRef
7.
Zurück zum Zitat Wang HL, Xing SY, Dong PS, Han YH, Zhu JH, Lai LH, Zhao JF (2014) Safety and efficay of intracoronary tirofiban administration in patients with serious thrombus burden and ST-elevation myocardial infarction undergoing percutaneous coronary intervention. Eur Rev Med Pharmocol Sci 18:3690–3695 Wang HL, Xing SY, Dong PS, Han YH, Zhu JH, Lai LH, Zhao JF (2014) Safety and efficay of intracoronary tirofiban administration in patients with serious thrombus burden and ST-elevation myocardial infarction undergoing percutaneous coronary intervention. Eur Rev Med Pharmocol Sci 18:3690–3695
8.
Zurück zum Zitat Motovaska Z, Hlimononaz O, Miklik M, Vrvaroovsk I et al (2016) Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention-multicenter randomized PRAGUE-18 study. Circulation 134:1603–1612CrossRef Motovaska Z, Hlimononaz O, Miklik M, Vrvaroovsk I et al (2016) Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention-multicenter randomized PRAGUE-18 study. Circulation 134:1603–1612CrossRef
9.
Zurück zum Zitat Montalescot G, Wiviott S, Braunwald E, Murphy S et al (2009) Prasugrel compared with clopidogel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double blind, randomised controlled trial. Lancet 373:723–732CrossRef Montalescot G, Wiviott S, Braunwald E, Murphy S et al (2009) Prasugrel compared with clopidogel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double blind, randomised controlled trial. Lancet 373:723–732CrossRef
10.
Zurück zum Zitat De Srvi S, Goedicke J, Ferlini M, Palmerini T (2016) Parasugrel versus clopidogrel in acute coronary syndromes treated with PCI: effects on clinical outcome according to culprit artery location. Int J Cardiol 223:632–638CrossRef De Srvi S, Goedicke J, Ferlini M, Palmerini T (2016) Parasugrel versus clopidogrel in acute coronary syndromes treated with PCI: effects on clinical outcome according to culprit artery location. Int J Cardiol 223:632–638CrossRef
Metadaten
Titel
Life after abciximab; what’s next for intracoronary thrombus?
verfasst von
D. McGhie
D. Amos
A. Elder
D. Brieger
H. C. Lowe
Publikationsdatum
25.10.2019
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 1/2020
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-019-01977-9

Weitere Artikel der Ausgabe 1/2020

Journal of Thrombosis and Thrombolysis 1/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.